Danielle A Swales1, Leah A Grande1, Deborah A Wing2, Michelle Edelmann3, Laura M Glynn4, Curt Sandman5, Roger Smith6, Maria Bowman6, Elysia Poggi Davis1,5. 1. Department of Psychology, University of Denver, Denver, Colorado. 2. Obstetrics and Gynecology, University of California, Irvine, Orange, California. 3. University of Colorado, Anschutz Medical Campus, Aurora, Colorado. 4. Department of Psychology, Chapman University, Orange, California. 5. Department of Psychiatry, University of California, Irvine, Irvine, California. 6. Mothers and Babies Research Centre, Hunter Medical Research Institute, Faculty of Health, University of Newcastle, Callaghan, New South Wales, Australia.
Abstract
Context: Antenatal corticosteroids are commonly administered to pregnant women at risk for delivering between 23 and 34 gestational weeks; they provide crucial benefits to fetal lung maturation and reduce risk for neonatal morbidity and mortality. Corticosteroids are maximally efficacious for lung maturation when administered within 2 to 7 days of delivery. Accurately identifying the timing of preterm delivery is thus critical to ensure that antenatal corticosteroids are administered within a week of delivery and to avoid unnecessary administration to women who will deliver at term. A plausible biomarker for predicting time of delivery is placental corticotropin-releasing hormone (pCRH). Objective: To assess whether pCRH concentrations predict time to delivery and specifically which women will deliver within a week of treatment. Design: pCRH concentrations were evaluated before administration of the corticosteroid betamethasone, and timing of delivery was recorded. Participants: A total of 121 women with singleton pregnancies who were prescribed betamethasone. Results: Elevated pCRH concentrations were associated with a shorter time from treatment to delivery. Receiver-operating characteristic curves revealed that pCRH may improve the precision of predicting preterm delivery. Conclusions: In the current sample, pCRH concentrations predicted the likelihood of delivering within 1 week of corticosteroid treatment. Current findings suggest that pCRH may be a diagnostic indicator of impending preterm delivery. Increasing the precision in predicting time to delivery could inform when to administer antenatal corticosteroids, thus maximizing benefits and reducing the likelihood of exposing fetuses who will be delivered at term.
Context: Antenatal corticosteroids are commonly administered to pregnant women at risk for delivering between 23 and 34 gestational weeks; they provide crucial benefits to fetal lung maturation and reduce risk for neonatal morbidity and mortality. Corticosteroids are maximally efficacious for lung maturation when administered within 2 to 7 days of delivery. Accurately identifying the timing of preterm delivery is thus critical to ensure that antenatal corticosteroids are administered within a week of delivery and to avoid unnecessary administration to women who will deliver at term. A plausible biomarker for predicting time of delivery is placental corticotropin-releasing hormone (pCRH). Objective: To assess whether pCRH concentrations predict time to delivery and specifically which women will deliver within a week of treatment. Design: pCRH concentrations were evaluated before administration of the corticosteroid betamethasone, and timing of delivery was recorded. Participants: A total of 121 women with singleton pregnancies who were prescribed betamethasone. Results: Elevated pCRH concentrations were associated with a shorter time from treatment to delivery. Receiver-operating characteristic curves revealed that pCRH may improve the precision of predicting preterm delivery. Conclusions: In the current sample, pCRH concentrations predicted the likelihood of delivering within 1 week of corticosteroid treatment. Current findings suggest that pCRH may be a diagnostic indicator of impending preterm delivery. Increasing the precision in predicting time to delivery could inform when to administer antenatal corticosteroids, thus maximizing benefits and reducing the likelihood of exposing fetuses who will be delivered at term.
Authors: Alex Polyakov; Saul Cohen; Marita Baum; Donna Trickey; Damien Jolley; Euan M Wallace Journal: Aust N Z J Obstet Gynaecol Date: 2007-02 Impact factor: 2.100
Authors: D P Behan; O Khongsaly; X J Liu; N Ling; R Goland; B Nasman; T Olsson; E B De Souza Journal: J Clin Endocrinol Metab Date: 1996-07 Impact factor: 5.958
Authors: Danielle A Swales; Leah A Grande; Deborah A Wing; Michelle Edelmann; Laura M Glynn; Curt Sandman; Roger Smith; Maria Bowman; Elysia Poggi Davis Journal: J Clin Endocrinol Metab Date: 2019-02-01 Impact factor: 5.958
Authors: Jessica Smith; Kellie E Murphy; Sarah D McDonald; Elizabeth Asztalos; Amir Aviram; Stefania Ronzoni; Elad Mei-Dan; Arthur Zaltz; Jon Barrett; Nir Melamed Journal: Arch Gynecol Obstet Date: 2022-01-18 Impact factor: 2.493
Authors: Robert C Johnston; Megan Faulkner; Philip M Carpenter; Ali Nael; Dana Haydel; Curt A Sandman; Deborah A Wing; Elysia Poggi Davis Journal: Reprod Sci Date: 2020-03-26 Impact factor: 3.060